Studying zonulin levels in patients with inflammatory bowel disease and peripheral arthritis
- 作者: Khusainova G.M.1, Nesmeyanova O.B.2, Dolgushina A.I.1, Abramovskikh O.S.1, Genkel V.V.1, Nikushkina K.V.1
-
隶属关系:
- South-Ural State Medical University
- Chelyabinsk Regional Clinical Hospital
- 期: 卷 15, 编号 3 (2023)
- 页面: 33-40
- 栏目: Original research
- URL: https://journals.eco-vector.com/vszgmu/article/view/582014
- DOI: https://doi.org/10.17816/mechnikov582014
- ID: 582014
如何引用文章
详细
BACKGROUND: Currently, disruption of the barrier function of the intestinal mucosa is considered one of the key mechanisms in the pathogenesis of extraintestinal manifestations of inflammatory bowel diseases, especially damage to the musculoskeletal system.
AIM: To study the relationship between the level of zonulin in blood serum and the parameters of the immune status in patients with inflammatory bowel diseases in combination with peripheral arthritis.
MATERIALS AND METHODS: 97 patients with ulcerative colitis and Crohn’s disease have been examined, with peripheral arthritis verified in 47 patients; the control group included 50 patients without peripheral arthritis. Zonulin, tumor necrosis factor α, interleukin-1β, -10, -17A, -23 were determined in blood serum using standard kits for direct enzyme immunoassay.
RESULTS: Patients with peripheral arthritis were younger with an earlier onset of inflammatory bowel diseases (p < 0.001). When assessing the concentration of serum zonulin in the patients with and without arthritis, no significant differences have been found. In the patients with peripheral arthritis, zonulin concentration directly correlated with the level of interleukin-17A (r = 0.323; p = 0.039), interleukin-23 (r = 0.321; p = 0.041).
CONCLUSIONS: According to the data obtained, the use of zonulin as a marker of peripheral arthritis in inflammatory bowel diseases is not recommended. Nevertheless, the correlation of zonulin and the concentrations of interleukin-17А and -23 demonstrates its role in the regulation of mucosal immunity in the development of extraintestinal manifestations of inflammatory bowel diseases.
全文:
作者简介
Guzel Khusainova
South-Ural State Medical University
编辑信件的主要联系方式.
Email: husainovagm@yandex.ru
ORCID iD: 0000-0001-5954-3112
SPIN 代码: 9660-5293
MD, Assistant
俄罗斯联邦, ChelyabinskOlga Nesmeyanova
Chelyabinsk Regional Clinical Hospital
Email: olganesmeyanova@mail.ru
MD, Cand. Sci. (Med.)
俄罗斯联邦, ChelyabinskAnastasia Dolgushina
South-Ural State Medical University
Email: dolgushinaai@yandex.ru
ORCID iD: 0000-0003-2569-1699
MD, Dr. Sci. (Med.), Professor
俄罗斯联邦, ChelyabinskOlga Abramovskikh
South-Ural State Medical University
Email: abramoschel@mail.ru
ORCID iD: 0000-0001-7086-5657
SPIN 代码: 6330-3570
MD, Dr. Sci. (Med.), Professor
俄罗斯联邦, ChelyabinskVadim Genkel
South-Ural State Medical University
Email: henkel-07@mail.ru
ORCID iD: 0000-0001-5902-3803
SPIN 代码: 2519-6100
MD, Cand. Sci. (Med.), Assistant Professor
俄罗斯联邦, ChelyabinskKarina Nikushkina
South-Ural State Medical University
Email: knikushkina81@gmail.com
ORCID iD: 0000-0002-3900-9278
SPIN 代码: 4216-6139
MD, Cand. Sci. (Med.)
俄罗斯联邦, Chelyabinsk参考
- Ivashkin VT, Shelygin YuA, Khalif IL, et al. Clinical guide of Russian association of gastroenterology and Russian association of coloproctology on diagnostics and treatment of ulcerative colitis. Koloproktologiya. 2017;(1(59)):6–30. (In Russ.)
- Ivashkin VT, Shelygin YuA, Khalif IL, et al. Clinical guide of Russian association of gastroenterology and Russian association of coloproctology on diagnostics and treatment of Crohn’s disease. Koloproktologiya. 2017;(2(60)):7–29. (In Russ.)
- Parfenov AI, Knyazev OV, Kagramanova AV. Systemic manifestations of inflammatory bowel diseases. Therapeutic Archive. 2020;92(2):4–11. (In Russ.) doi: 10.26442/00403660.2020.02.000535
- Hedin CRH, Vavricka SR, Stagg AJ, et al. The pathogenesis of extraintestinal manifestations: Implications for IBD research, diagnosis, and therapy. J Crohns Colitis. 2019;13(5):541–554. doi: 10.1093/ecco-jcc/jjy191
- Wang CR, Tsai HW. Seronegative spondyloarthropathy-associated inflammatory bowel disease. World J Gastroenterol. 2023;29(3):450–468. doi: 10.3748/wjg.v29.i3.450
- Ben Nessib D, Ferjani H, Maatallah K, et al. Update on therapeutic management of spondyloarthritis associated with inflammatory bowel disease. Clin Rheumatol. 2020;39(12):3543–3553. doi: 10.1007/s10067-020-05136-x
- Rumyantseva DG, Erdes ShF. Axial spondyloarthritis: a current look at the concept and evolution of the disease. Modern Rheumatology Journal. 2019;13(4):4–10. (In Russ.) DOI: 10/14412/1996-7012-2019-4-4-10
- Khusainova GM, Dolgushina AI, Kuznetcova AS. Characteristics of the articular syndrome in patients with inflammatory bowel disease. Experimental and Clinical Gastroenterology. 2020;178(6):95–100. (In Russ.) doi: 10.31146/1682-8658-ecg-178-6-95-100
- Di Jiang C, Raine T. IBD considerations in spondyloarthritis. Ther Adv Musculoskelet Dis. 2020;12:1759720X20939410. doi: 10.1177/1759720X20939410
- Pedersen SJ, Maksymowych WP. The Pathogenesis of ankylosing spondylitis: an update. Curr Rheumatol Rep. 2019;21(10):58. doi: 10.1007/s11926-019-0856-3
- Galushko EA, Gordeev AV. Gut microbiome and spondyloarthritis. Experimental and Clinical Gastroenterology. 2019;162(2):120–124. (In Russ.) doi: 10.31146/1682-8658-ecg-162-2-120-124
- Qaiyum Z, Lim M, Inman RD. The gut-joint axis in spondyloarthritis: immunological, microbial, and clinical insights. Semin Immunopathol. 2021;43(2):173–192. doi: 10.1007/s00281-021-00845-0
- Osikov MV, Grechishkin MV, Shishkova YuS. State of the microbiota and local immune factors in inflammatory bowel diseases and selection of the experimental model. Yuzhno-Ural’skij medicinskij zhurnal. 2023;1:50–59. (In Russ.)
- Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011;91(1):151–175. doi: 10.1152/physrev.00003.2008
- Fasano A. All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases. F1000Res. 2020;31(9):F1000 Faculty Rev-69. doi: 10.12688/f1000research.20510.1
- Russian clinical guidelines. Rheumatology. Ed. by E.L. Nasonov. Moscow: GEOTAR-Media; 2017. (In Russ.)
- Ciccia F, Guggino G, Rizzo A, et al. Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis. Ann Rheum Dis. 2017;76(6):1123–1132. doi: 10.1136/annrheumdis-2016-210000
- Nasonov EL, Korotaeva TV, Rodolfi S, Selmi CF. Prospects for the use of monoclonal antibodies to interleukin 23 Gusеlkumab in psoriatic arthritis: New data. Rheumatology Science and Practice. 2022;60(1):80–90. (In Russ.) doi: 10.47360/1995-4484-2022-80-90
- Chmielińska M, Olesińska M, Romanowska-Próchnicka K, Szukiewicz D. Haptoglobin and its related protein, zonulin – what is their role in spondyloarthropathy? J Clin Med. 2021;10(5):1131. doi: 10.3390/jcm10051131
- Zybina NN, Nikonov EL, Gershtein ES, et al. Zonulin is a marker of epithelial and endothelial barrier functions in non-communicable diseases (narrative review). Russian Journal of Evidence-based Gastroenterology. 2022;11(1):28–44. (In Russ.) doi: 10.17116/dokgastro20221101128
- Wang X, Memon AA, Palmér K, et al. The association of zonulin-related proteins with prevalent and incident inflammatory bowel disease. BMC Gastroenterol. 2022;22(1):3. doi: 10.1186/s12876-021-02075-y